Rectal suppositories of 8-methoxsalen produce fewer gastrointestinal side effects than the oral formulation

Journal of the American Academy of Dermatology

Volumn 35, Issue 3 PART I, 1996, Pages 424-427

  Bolognia, Jean L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOXSALEN;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSORIASIS; PUVA; VOMITING;

ABDOMINAL PAIN; ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; CRYSTALLIZATION; HEADACHE; HUMANS; INTESTINES; METHOXSALEN; NAUSEA; PILOT PROJECTS; PSORIASIS; PUVA THERAPY; SOLUTIONS; STOMACH; SUPPOSITORIES; VOMITING;

EID: 0029757512     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0190-9622(96)90609-x     Document Type: Article

References (3)

1. Sullivan TJ, Walter JL, Kouba RF, et al. Bioavailability of a new oral methoxsalen formulation. Arch Dermatol 1986; 122:768-71.
2. Lassus A, Halme K, Eskelinen A, et al. Treatment of vitiligo with oral methoxsalen and UVA. Photodermatology 1984;1:170-3.
3. George SA, Ferguson J. Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute nonphototoxic adverse effects. Photodermatol Photoimmunol Photomed 1992; 9:33-5.